PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
9.16%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt would investigate if growth quality matches quantity.
8.72%
Cost growth of 8.72% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify cost control.
10.92%
Growth of 10.92% versus flat Medical - Pharmaceuticals gross profit. Walter Schloss would verify quality.
1.61%
Margin change of 1.61% versus flat Medical - Pharmaceuticals margins. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.22%
Other expenses change of 22.22% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify efficiency.
0.94%
Operating expenses growth 1.1-1.25x Medical - Pharmaceuticals median of 0.77%. John Neff would investigate control.
7.33%
Total costs growth exceeding 1.5x Medical - Pharmaceuticals median of 2.30%. Jim Chanos would check for waste.
43.33%
Interest expense change of 43.33% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify control.
48.66%
D&A growth exceeding 1.5x Medical - Pharmaceuticals median of 3.74%. Jim Chanos would check for overinvestment.
66.79%
EBITDA growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
52.80%
Margin change of 52.80% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
81.54%
Operating income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
66.31%
Margin change of 66.31% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
10.78%
Other expenses growth while Medical - Pharmaceuticals reduces costs. Peter Lynch would examine differences.
72.16%
Pre-tax income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
57.72%
Pre-tax margin growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
70.58%
Tax expense growth while Medical - Pharmaceuticals reduces burden. Peter Lynch would examine differences.
73.81%
Net income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
59.23%
Margin change of 59.23% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
75.54%
EPS change of 75.54% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
75.54%
Diluted EPS change of 75.54% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.